-
作者:Nummedal, Tara
作者单位:Brown University
-
作者:Pawley, Emily
-
作者:Guerrini, Anita
-
作者:Ram, Ranit; Xia, Lu; Benzidi, Hind; Guha, Anku; Golovanova, Viktoria; Garzon Manjon, Alba; Llorens Rauret, David; Sanz Berman, Pol; Dimitropoulos, Marinos; Mundet, Bernat; Pastor, Ernest; Celorrio, Veronica; Mesa, Camilo A.; Das, Aparna M.; Pinilla-Sanchez, Adrian; Gimenez, Sixto; Arbiol, Jordi; Lopez, Nuria; Garcia de Arquer, F. Pelayo
作者单位:Barcelona Institute of Science & Technology; Universitat Politecnica de Catalunya; Institut de Ciencies Fotoniques (ICFO); Barcelona Institute of Science & Technology; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Barcelona; Barcelona Institute of Science & Technology; Catalan Institute of Nanoscience & Nanotechnology (ICN2); Barcelona Institute of Science & Technology; Autonomous University of Barcelona; Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); University of Tokyo; Diamond Light Source; Universitat Jaume I; ICREA
摘要:The oxygen evolution reaction is the bottleneck to energy-efficient water-based electrolysis for the production of hydrogen and other solar fuels. In proton exchange membrane water electrolysis (PEMWE), precious metals have generally been necessary for the stable catalysis of this reaction. In this work, we report that delamination of cobalt tungstate enables high activity and durability through the stabilization of oxide and water-hydroxide networks of the lattice defects in acid. The resulti...
-
作者:Clery, Daniel
-
作者:Stokstad, Erik
-
作者:Brainard, Jeffrey
-
作者:de Magalhes, Joo Pedro
作者单位:University of Birmingham
-
作者:Mathew, Divij; Marmarelis, Melina E.; Foley, Caitlin; Bauml, Joshua M.; Ye, Darwin; Ghinnagow, Reem; Ngiow, Shin Foong; Klapholz, Max; Jun, Soyeong; Zhang, Zhaojun; Zorc, Robert; Davis, Christiana W.; Diehn, Maximillian; Giles, Josephine R.; Huang, Alexander C.; Hwang, Wei-Ting; Zhang, Nancy R.; Schoenfeld, Adam J.; Carpenter, Erica L.; Langer, Corey J.; Wherry, E. John; Minn, Andy J.
作者单位:University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Stanford University; Stanford Cancer Institute; Stanford University; University of Pennsylvania; University of Pennsylvania; Memorial Sloan Kettering Cancer Center
摘要:Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti-PD-1 (programmed cell death protein 1) immunotherapy improves immune function and antitumor responses in mice and results in high response rates (67%) in a phase 2 clinical trial for metastatic non-small cell lung cancer. Patients who failed to respond to initial anti-PD-1 immunotherapy but responde...
-
作者:Zak, Jaroslav; Pratumchai, Isaraphorn; Marro, Brett S.; Marquardt, Kristi L.; Zavareh, Reza Beheshti; Lairson, Luke L.; Oldstone, Michael B. A.; Varner, Judith A.; Hegerova, Livia; Cao, Qing; Farooq, Umar; Kenkre, Vaishalee P.; Bachanova, Veronika; Teijaro, John R.
作者单位:Scripps Research Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Scripps Research Institute; University of California System; University of California San Diego; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; University of Iowa; University of Wisconsin System; University of Wisconsin Madison; University of Minnesota System; University of Minnesota Twin Cities
摘要:Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in cancer patients, but clinical responses are limited. Cytokine signaling through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway correlates with checkpoint immunotherapy resistance. We report a phase I clinical trial of the JAK inhibitor ruxolitinib with anti-PD-1 antibody nivolumab in Hodgkin lymphoma patients relapsed or refractory following checkpoint inhibitor im...